Myasthenia Gravis Exacerbation Following COVID-19 Vaccine: A Case Report
Background: Vaccination remains the mainstay of strategy for prevention of Coronavirus Disease-2019 (COVID-19). AZD1222 (AstraZeneca vaccine) was distributed in Sudan by the COVID-19 Vaccines Global Access facility in March 2021. It was added to the emergency use list by the WHO in mid-February 202...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University Library System, University of Pittsburgh
2023-03-01
|
| Series: | International Journal of Medical Students |
| Subjects: | |
| Online Access: | https://ijms.info/IJMS/article/view/1455 |
| _version_ | 1797695498109321216 |
|---|---|
| author | Thoybah Yousif Ibrahim Gabralla Hayat Abdoallah Ahmed Bashir Omaima Abdalla Hajahmed Mohamed |
| author_facet | Thoybah Yousif Ibrahim Gabralla Hayat Abdoallah Ahmed Bashir Omaima Abdalla Hajahmed Mohamed |
| author_sort | Thoybah Yousif Ibrahim Gabralla |
| collection | DOAJ |
| description |
Background: Vaccination remains the mainstay of strategy for prevention of Coronavirus Disease-2019 (COVID-19). AZD1222 (AstraZeneca vaccine) was distributed in Sudan by the COVID-19 Vaccines Global Access facility in March 2021. It was added to the emergency use list by the WHO in mid-February 2021. However, vaccine safety among patients with autoimmune diseases, such as myasthenia gravis (MG), is yet to be established. MG is a relatively rare illness that could result in life-threatening complications. Myasthenic crisis is considered the most serious complication of MG that can lead to death due to aspiration and respiratory failure.
The case: We report the case of a 37-year-old Sudanese female who presented to the emergency room with an exacerbation of her normally well-controlled MG following her second dose of AZD1222 vaccination. She continued to deteriorate and was admitted to the intensive care unit, where she was intubated and placed on a mechanical ventilator. The low-income setting was a major barrier in obtaining intravenous immunoglobulin until the patient died. Our study aims to present an MG case with features of MG exacerbation following administration of a second dose of AZD1222.
Conclusion: Little is known about the effect of different COVID-19 vaccines on subgroups of patients with autoimmune diseases like MG. In our case, an exacerbation of MG may have been precipitated by the COVID-19 AstraZeneca vaccine. Therefore, more efforts and experimental studies may be needed, with closer vigilance in MG patients
|
| first_indexed | 2024-03-12T03:13:16Z |
| format | Article |
| id | doaj.art-736e28936ffa4e6cbedef3de6393df96 |
| institution | Directory Open Access Journal |
| issn | 2076-6327 |
| language | English |
| last_indexed | 2024-03-12T03:13:16Z |
| publishDate | 2023-03-01 |
| publisher | University Library System, University of Pittsburgh |
| record_format | Article |
| series | International Journal of Medical Students |
| spelling | doaj.art-736e28936ffa4e6cbedef3de6393df962023-09-03T14:19:29ZengUniversity Library System, University of PittsburghInternational Journal of Medical Students2076-63272023-03-0111110.5195/ijms.2023.1455Myasthenia Gravis Exacerbation Following COVID-19 Vaccine: A Case ReportThoybah Yousif Ibrahim Gabralla0Hayat Abdoallah Ahmed Bashir1Omaima Abdalla Hajahmed Mohamed2House officer. Al-Shuhada Hospital, Khartoum, Sudan.Fifth-year Medical Student. University of Khartoum, Khartoum, Sudan.Medical officer at Alribat teatching hospital- Emergency department- Khartoum, Sudan. Background: Vaccination remains the mainstay of strategy for prevention of Coronavirus Disease-2019 (COVID-19). AZD1222 (AstraZeneca vaccine) was distributed in Sudan by the COVID-19 Vaccines Global Access facility in March 2021. It was added to the emergency use list by the WHO in mid-February 2021. However, vaccine safety among patients with autoimmune diseases, such as myasthenia gravis (MG), is yet to be established. MG is a relatively rare illness that could result in life-threatening complications. Myasthenic crisis is considered the most serious complication of MG that can lead to death due to aspiration and respiratory failure. The case: We report the case of a 37-year-old Sudanese female who presented to the emergency room with an exacerbation of her normally well-controlled MG following her second dose of AZD1222 vaccination. She continued to deteriorate and was admitted to the intensive care unit, where she was intubated and placed on a mechanical ventilator. The low-income setting was a major barrier in obtaining intravenous immunoglobulin until the patient died. Our study aims to present an MG case with features of MG exacerbation following administration of a second dose of AZD1222. Conclusion: Little is known about the effect of different COVID-19 vaccines on subgroups of patients with autoimmune diseases like MG. In our case, an exacerbation of MG may have been precipitated by the COVID-19 AstraZeneca vaccine. Therefore, more efforts and experimental studies may be needed, with closer vigilance in MG patients https://ijms.info/IJMS/article/view/1455Myasthenia Gravis COVID-19 VaccineCase Report |
| spellingShingle | Thoybah Yousif Ibrahim Gabralla Hayat Abdoallah Ahmed Bashir Omaima Abdalla Hajahmed Mohamed Myasthenia Gravis Exacerbation Following COVID-19 Vaccine: A Case Report International Journal of Medical Students Myasthenia Gravis COVID-19 Vaccine Case Report |
| title | Myasthenia Gravis Exacerbation Following COVID-19 Vaccine: A Case Report |
| title_full | Myasthenia Gravis Exacerbation Following COVID-19 Vaccine: A Case Report |
| title_fullStr | Myasthenia Gravis Exacerbation Following COVID-19 Vaccine: A Case Report |
| title_full_unstemmed | Myasthenia Gravis Exacerbation Following COVID-19 Vaccine: A Case Report |
| title_short | Myasthenia Gravis Exacerbation Following COVID-19 Vaccine: A Case Report |
| title_sort | myasthenia gravis exacerbation following covid 19 vaccine a case report |
| topic | Myasthenia Gravis COVID-19 Vaccine Case Report |
| url | https://ijms.info/IJMS/article/view/1455 |
| work_keys_str_mv | AT thoybahyousifibrahimgabralla myastheniagravisexacerbationfollowingcovid19vaccineacasereport AT hayatabdoallahahmedbashir myastheniagravisexacerbationfollowingcovid19vaccineacasereport AT omaimaabdallahajahmedmohamed myastheniagravisexacerbationfollowingcovid19vaccineacasereport |